通过调节氧化来拯救阻塞性睡眠呼吸暂停-睡眠暂停综合征中的血管内皮细胞
Qi Chen1,2, Dandan Jiang1,2, Jie He1,3
1School of Clinical Medicine, Chengdu Medical College, Chengdu, China.
Journal of thoracic disease
|December 11, 2025
概括
分子 (H2) 通过减少氧化应激和改善氧化 (NO) 途径,防止阻塞性睡眠呼吸暂停-呼吸暂停综合征 (OSAHS). 这种抗氧化疗法显示出减轻与OSAHS相关的心血管风险的前景.
科学领域:
- 心血管研究研究心血管研究
- 氧化压力生物学 氧化压力生物学
- 睡眠医学 睡眠医学
背景情况:
- 阻塞性睡眠呼吸暂停-呼吸暂停综合征 (OSAHS) 导致慢性间歇性缺氧 (IH),导致内皮功能障碍和心血管风险增加.
- 氧化应激和破坏的氧化 (NO) 恒温是OSAHS诱导的血管损伤的关键机制.
- 分子 (H2) 是一种选择性抗氧化剂,具有潜在的治疗益处,但其对与OSAHS相关的内皮损伤的保护作用需要进一步研究.
研究的目的:
- 调查H2在OSAHS中保持内皮功能的能力.
- 通过阐明潜在的分子通路,确定H2是否恢复了NO的生物可用性.
- 评估H2对OSAHS中氧化应激,炎症和亡的影响.
主要方法:
- 使用的转化模型:体外 (人静脉内皮细胞) 和体内 (OSAHS大鼠模型) 接受间歇性缺氧 (IH).
- 在体外和体内吸入H2的H2丰富介质.
- 评估了氧化应激标志物 (ROS,MDA),NO途径组件 (eNOS酸化,BH4/BH2比率),炎症 (TNF-α,ICAM-1) 和亡.
主要成果:
- 在细胞和动物模型中,H2显著降低了IH诱导的氧化应激 (ROS,MDA).
- H2通过增强eNOS酸化并保持BH4/BH2比率来恢复NO的生物可用性,防止eNOS脱.
- 在OSAHS大鼠中,H2治疗改善了内皮依赖血管扩张,减弱了血管重塑,抑制了炎症,并减少了内皮亡.
结论:
- 通过多方面的保护机制,H2有效地减轻与OSAHS相关的内皮功能障碍.
- H2调节氧化还原稳定,通过eNOS复合增强NO的产生,并抑制炎症和亡.
- H2在OSAHS患者心血管并发症的辅助治疗中显示出显著的治疗潜力.
相关概念视频
Sleep Apnea
449
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
449
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
554
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
554
Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K
Nitric Oxide Signaling Pathway
6.1K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
424
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
424
Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235


